Summary statistics - quantitative results

EQA round: APLA2/26 - Antiphospholipid Antibodies

Deadline: 25.9.2026

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average
SD = standard deviation
CV = coefficient of variation
N_{tot} = total number of the results
N_{out} = number of the results removed before calculation
AV = assigned value
CVP = consensus of all participants
U_{AV} = expanded uncertainty of the assigned value (k = 2)
D_{max} = acceptable difference
LL = lower limit
UL = upper limit
N_{eva} = number of the results assessed
N_{suc} = number of successful results
S_{rel} = relative success

Test / Sample / Group	[unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability	AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel} [%]
(465) **anti-β2-glycoprotein 1 screening**	[kU/L]				10								0		
Sample A		0,685	0,47	68	10								0		
(135) OrgenTec		0,8	0,15	19	6	0	CVP	0,685	0,36	25%	0,513	0,857	0		
Other					4	2							0		
							1x 38, 1x 49, 2x 148								
Sample B		14,1	11	82	10								0		
(135) OrgenTec		11,6	2,5	22	6	0	CVP	14,1	8,7	25%	10,5	17,7	0		
Other					4	2							0		
							1x 38, 1x 49, 2x 148								
(467) **anti-β2-glycoprotein 1 IgG**	[kU/L]				60								0		
Sample A		2,84	4,2	150	60								0		
(34) Sebia		0,53	0,25	48	5	1	CVP	2,84	1,5	25%	2,13	3,55	0		
(38) Werfen (IL)		11,1	3,5	32	6	2	CVP	2,84	1,5	25%	2,13	3,55	0		
(87) Euroimmun		0,66	0,83	130	7	2	CVP	2,84	1,5	25%	2,13	3,55	0		
(135) OrgenTec		0,532	0,44	83	15	0	CVP	2,84	1,5	25%	2,13	3,55	0		
(166) Thermo Fisher		0,7	0,15	21	8	1	CVP	2,84	1,5	25%	2,13	3,55	0		
(211) INOVA Diagnostics		11,1	2,5	23	12	3	CVP	2,84	1,5	25%	2,13	3,55	0		
Other					7	3							0		
							1x 49, 1x 115, 1x 140, 2x 148, 1x 183, 1x 999								
Sample B		5,11	5,9	120	60								0		
(34) Sebia		3,45	0,97	28	5	1	CVP	5,11	2,1	25%	3,83	6,39	0		
(38) Werfen (IL)		19,4	4,1	21	6	2	CVP	5,11	2,1	25%	3,83	6,39	0		
(87) Euroimmun		1,44	0,83	58	7	2	CVP	5,11	2,1	25%	3,83	6,39	0		
(135) OrgenTec		2,1	1,1	52	15	0	CVP	5,11	2,1	25%	3,83	6,39	0		
(166) Thermo Fisher		2,25	0,22	9,9	8	1	CVP	5,11	2,1	25%	3,83	6,39	0		
(211) INOVA Diagnostics		14,8	2,4	16	12	3	CVP	5,11	2,1	25%	3,83	6,39	0		
Other					7	3							0		
							1x 49, 1x 115, 1x 140, 2x 148, 1x 183, 1x 999								
(468) **anti-β2-glycoprotein 1 IgM**	[kU/L]				59								0		
Sample A		0,958	1	100	59								0		
(34) Sebia		0,35	0,074	21	5	1	CVP	0,958	0,36	25%	0,718	1,2	0		
(38) Werfen (IL)		0,55	0,82	150	6	2	CVP	0,958	0,36	25%	0,718	1,2	0		
(87) Euroimmun		1	1,5	150	6	2	CVP	0,958	0,36	25%	0,718	1,2	0		
(135) OrgenTec		0,388	0,33	84	15	0	CVP	0,958	0,36	25%	0,718	1,2	0		
(166) Thermo Fisher		2,65	0,37	14	8	1	CVP	0,958	0,36	25%	0,718	1,2	0		
(211) INOVA Diagnostics		1,1	0	0	12	3	CVP	0,958	0,36	25%	0,718	1,2	0		
Other					7	3							0		
							1x 49, 1x 115, 1x 140, 2x 148, 1x 183, 1x 999								
Sample B		25,4	10	40	59								0		
(34) Sebia		21	5,9	28	5	1	CVP	25,4	3,7	25%	19	31,8	0		
(38) Werfen (IL)		33,8	2,9	8,6	6	2	CVP	25,4	3,7	25%	19	31,8	0		
(87) Euroimmun		79	120	150	6	2	CVP	25,4	3,7	25%	19	31,8	0		
(135) OrgenTec		18,7	6,9	37	15	0	CVP	25,4	3,7	25%	19	31,8	0		
(166) Thermo Fisher		20,5	0,74	3,6	8	1	CVP	25,4	3,7	25%	19	31,8	0		
(211) INOVA Diagnostics		32,2	2,4	7,6	12	3	CVP	25,4	3,7	25%	19	31,8	0		
Other					7	3							0		
							1x 49, 1x 115, 1x 140, 2x 148, 1x 183, 1x 999								
(461) **anti-cardiolipin screening**	[kU/L]				12								0		
Sample A		1,25	0,074	5,9	12								0		
(135) OrgenTec		1,15	0,22	19	6	0	CVP	1,25	0,092	25%	0,937	1,57	0		
Other					6	3							0		
							2x 34, 1x 38, 3x 148								
Sample B		19,9	4,6	23	12								0		
(135) OrgenTec		17,8	3,8	21	6	0	CVP	19,9	5,7	25%	14,9	24,9	0		
Other					6	3							0		
							2x 34, 1x 38, 3x 148								
(463) **anti-cardiolipin IgG**	[kU/L]				63								0		
Sample A		1,88	2,3	120	63								0		
(34) Sebia		0,915	1,3	140	5	1	CVP	1,88	0,78	25%	1,41	2,35	0		
(38) Werfen (IL)		5,35	0,52	9,7	7	2	CVP	1,88	0,78	25%	1,41	2,35	0		
(87) Euroimmun		0,75	0,55	73	7	2	CVP	1,88	0,78	25%	1,41	2,35	0		
(135) OrgenTec		0,766	0,8	100	16	0	CVP	1,88	0,78	25%	1,41	2,35	0		
(166) Thermo Fisher		0,5	0	0	8	1	CVP	1,88	0,78	25%	1,41	2,35	0		
(211) INOVA Diagnostics		6,1	1	17	11	3	CVP	1,88	0,78	25%	1,41	2,35	0		

Summary statistics - quantitative results

EQA round: APLA2/26 - Antiphospholipid Antibodies

Deadline: 25.9.2026

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

Test / Sample / Group	[unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability	AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel} [%]
Other					9	3							0		
							2x 49, 1x 115, 1x 140, 3x 148, 1x 183, 1x 999								
Sample B		3,61	2,1	58	63								0		
(34) Sebia		2,25	2,9	130	5	1	CVP	3,61	0,72	25%	2,7	4,52	0		
(38) Werfen (IL)		5,8	0,89	15	7	2	CVP	3,61	0,72	25%	2,7	4,52	0		
(87) Euroimmun		2,47	1,2	50	7	2	CVP	3,61	0,72	25%	2,7	4,52	0		
(135) OrgenTec		2,85	1,2	43	16	0	CVP	3,61	0,72	25%	2,7	4,52	0		
(166) Thermo Fisher		2,65	0,37	14	8	1	CVP	3,61	0,72	25%	2,7	4,52	0		
(211) INOVA Diagnostics		6,4	0,89	14	11	3	CVP	3,61	0,72	25%	2,7	4,52	0		
Other					9	3							0		
							2x 49, 1x 115, 1x 140, 3x 148, 1x 183, 1x 999								
(464) **anti-cardiolipin IgM**	[kU/L]				63								0		
Sample A		0,616	0,46	74	63								0		
(38) Werfen (IL)		1	0	0	7	2	CVP	0,616	0,16	25%	0,462	0,77	0		
(87) Euroimmun		0,55	0,67	120	7	2	CVP	0,616	0,16	25%	0,462	0,77	0		
(135) OrgenTec		0,354	0,25	70	17	0	CVP	0,616	0,16	25%	0,462	0,77	0		
(166) Thermo Fisher		0,85	0,074	8,7	8	1	CVP	0,616	0,16	25%	0,462	0,77	0		
(211) INOVA Diagnostics		1	0	0	11	3	CVP	0,616	0,16	25%	0,462	0,77	0		
Other					13	4							0		
							4x 34, 2x 49, 1x 115, 1x 140, 3x 148, 1x 183, 1x 999								
Sample B		24,2	10	41	63								0		
(38) Werfen (IL)		35,2	2,7	7,6	7	2	CVP	24,2	3,4	25%	18,1	30,3	0		
(87) Euroimmun		12,2	1,5	12	7	2	CVP	24,2	3,4	25%	18,1	30,3	0		
(135) OrgenTec		22	8,1	37	17	0	CVP	24,2	3,4	25%	18,1	30,3	0		
(166) Thermo Fisher		21	3	14	8	1	CVP	24,2	3,4	25%	18,1	30,3	0		
(211) INOVA Diagnostics		34,3	2,3	6,7	11	3	CVP	24,2	3,4	25%	18,1	30,3	0		
Other					13	4							0		
							4x 34, 2x 49, 1x 115, 1x 140, 3x 148, 1x 183, 1x 999								